The Mobile App Ecosystem in Pharma - HCL Technologies€¦ · and how HCL can provide solutions to...

The Mobile AppEcosystem inPharma

WHITEPAPER December 2015

AUTHOR:ADITI CHAKRABORTY

2

TABLE OF CONTENTSINTRODUCTION 3-4

THE CURRENT STATE OF MOBILE APPS IN PHARMA 4-10

FACTORS INFLUENCING THE ADOPTION OF MOBILE APPS 11-13

Where HCL Can Help 14-15

REFERENCES 16-18

ACKNOWLEDGEMENTS 18

The Mobile App Ecosystem in Pharma | december 2015

© 2015, HCL TECHNOLOGIES. REPRODUCTION PROHIBITED. THIS DOCUMENT IS PROTECTED UNDER COPYRIGHT BY THE AUTHOR, ALL RIGHTS RESERVED.

IntroductionEnhancing customer experience, effectively engaging with the customer, building a connected patient health ecosystem, and ensuring robust collaboration between key stakeholders across the drug development value chain are some of the key digital trends observed for Pharma. An ecosystem of connected people, information, technologies, systems, and devices is what they all envision.

In the last few years, the focus of the pharmaceutical and life sciences companies has been on providing an effective collaboration platform for multiple stakeholders; their mission being to translate, share, and disseminate knowledge across the industry. This involves leveraging and harnessing the power of connected digital technologies and building advanced decision support systems with predictive analytics capabilities, on large sets of data and information, for real-time insights.

Consumers in today’s digital economy also demand the same level of experience, usability, connectivity, simplicity, and efficiency that they get from native, digital-born organizations (the experiences of Apple, the ubiquity of Google, the content of YouTube, to name a few) in their daily life. The pharmaceutical companies need to take these factors into consideration to not only improve upon its salesforce outreach but to also ensure an effective customer engagement.

Pharmaceutical companies could also leverage digital health technologies to bring additional value adds into their products. For example, they can take the help of smaller companies, which specialize in digital technologies, to develop new ways to add an advanced digital health companion to a cheap drug. This in turn can help them price the drug at a premium.

Though there is an initial spend on digitalization in terms of investment, it is no longer perceived as being just a cost-saving and a resource optimization initiative, but as a tool and an enabler that brings added benefits in the delivery of performance and quality.

Of the various digital technologies that enhance interaction, mobile technologies have been especially impactful. They have enabled companies to not only improve operational efficiencies, but also engage more effectively with customers and tap into new sources of revenue. Adoption of mobility is

3© 2015, HCL TECHNOLOGIES. REPRODUCTION PROHIBITED. THIS DOCUMENT IS PROTECTED UNDER COPYRIGHT BY THE AUTHOR, ALL RIGHTS RESERVED.

no longer a choice but a road to sustenance. The adoption of mobility can empower life sciences organizations to:

• Improve workflow efficiency by 10–25% by eliminating paper-based processes

• Increase patient recruitment in trials while cutting costs by up to 25%• Decrease counterfeit medicines to increase sales by 15-20%• Increase penetration of promotional activities and increasing sales

productivity by 12-15%• Ensure drug adherence and improving the effectiveness of clinical trials• Increase brand awareness and improve brand/company loyalty• Reduce costs by promoting easy accessibility and affordability; Example:

USD 0.4Mn (up to 8% of cost per study) in Phase 1, USD 2.4Mn (up to 12% of cost per study) in Phase 2, USD 6.1Mn (up to 12% of cost per study) in Phase 3, and USD 6.7Mn (up to 13% of cost per study) in Phase 4.

In this paper, we take a look at one of the key components of mobility—Mobile Apps. We look at how pharmaceutical companies are leveraging mobile apps to transform the life sciences industry by offering value propositions for each of the different stakeholders in the pharmaceutical value chain, the current state of mobile apps across leading pharmaceutical companies, factors impacting the efficacy of mobile apps and how HCL can provide solutions to pharmaceutical companies in this context.

The Current State of Mobile Apps in PharmaPharmaceutical companies have a lot of apps in the market, and have been focusing on using mobile apps to reach out to customers as well as derive business benefits. • There are more than 20000 medical/healthcare apps available in Apple’s

iTunes App Store alone. mHealth apps are the third-fastest growing app category for both iPhone and Android phones. The mobile health market is set to reach USD 26 billion by 2017. 1

• It is estimated that, by 2018, more than 50% of 3.4 billion smart phone and tablet users would download healthcare mobile apps.2 Of these users, most would be professionals, consumers and patients.

• Close to 90% of the doctors’ use smartphones and medical apps. 3 56% of doctors who use mobile devices say they expedite decision making.4

82% of oncologists consult their mobile device 4 or more times a day.5

• Tablet adoption among physicians increased from 62% to 72% (2014, Manhattan Institute)

Leveraging the results of a study across 23 biopharmaceutical companies6, we take a closer look to understand the mobile apps development and publishing patterns for the pharmaceutical companies—across therapeutic areas, app categories and user groups they are targeting and what purposes attribute to the priority areas for investing in mobile apps. To give a comprehensive perspective, a sample size of 1089 published apps was looked at both across the iOS and Android platforms.

Comparison of number of apps to revenue ratioIt has been found that there is lot of variation in app publishing across leading pharma companies. The number of mobile apps of individual companies has no major correlation with revenues. While there can be various reasons for this behavior, we have found that one of primary reasons is that some of the companies have been early to realize the potential of collaboration with technology start-up companies to research on how mHealth, digital and data analytics can be leveraged for increasing clinical value and market reach.

_____________________________________________________________________________________________1. Global Mobile Health Market Report 2013-2017,

http://research2guidance.com/2013/03/07/the-market-for-mhealth-app-services-will-reach-26-billion-by-

2017/2.http://www.techilasolutions.com/mobile-app-playing-an-important-role-in-healthcare-industry/ 3. Mobile Devices and Apps for Health Care Professionals: Uses and Benefits,

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029126/4. Remote/Mobile Health Monitoring Holds Potential,

http://www.marketingcharts.com/online/remotemobile-health-monitoring-holds-potential-14133/ 5. DigiPharm - Multiscreen Healthcare: Doctors, Pharma and Patients use of Mobile,

http://www.slideshare.net/sammielw/digipharm-multiscreen-healthcare 6. Study of 1089 published apps across multiple mobile platforms for 23 leading pharma companies

conducted in May 2015































Stakeholder Key Mobility Impact Areas

Patients

1. Promote patient empowerment and effective decision making by increasing self-management

2. Impart medical and product knowledge

3. Real-time collaboration and communication with HCPs and other patient advocacy groups and support networks

4. Personalized HCP-patient engagement platform e.g. personalized alerts or triggers from mobile devices based on the understanding/inputs from the HCP

5. Scheduling and virtual lab visits

6. Disease outbreak/surveillance/causal agent forecasting

HCPs(Physicians, Nurses, Patient Support groups

and other healthcare providers)

1. Clinical decision support through real-time data and analytics

2. Personal information repository through references, literature search portals, RxGuide, medical calculators, e-learning, etc as well as undertaking skill assessment tests and trainings etc.

3. Information on breakthrough therapies and surgical techniques, trials, patient support programs, drug pricing/co-payment etc.

4. Smartphones as diagnostic/testing/screening/measurement tools

5. Access product information to act as a diagnosis decision support tool and compare similar products (competitive landscape, Brand info, etc)

6. Time and event management tool to manage web meetings, conferencing, appointments, schedules, campaigns, virtual medical conferences

7. Organizing and managing data and information e.g. notes, audio, video

8. Collaboration and communication channels with other stakeholders

9. Remote patient monitoring and medication management

Sales Reps/ Field Sales

1. Sales activities such as analytics, reports, dashboard on the mobile including simulation scenarios

2. Business intelligence to identify the target group (consumers) and their usage pattern/trends so as to come up with ways to

group etc.)

3. Time and virtual event management

5. Medical knowledge/product information with a quick and simple search interface but a robust search engine

6. Promote brand awareness, ensure brand loyalty/consistency, brand re-use and patient pool retention even in case of a treatment switch

interaction and relationship management

Clinical Trial Personnel/

Support Staff

1. Recruitment and retention of clinical trial subjects

2. Reporting of ADRs, other data collection related activities

capabilities of the backend database

4. Clinical decision support

5. Collaboration and data sharing activities including real-time access to trial data

6. Improvement in workplace productivity, streamlined processes and reduction in data capture errors

Pharmacists/ Store Personnel/

Suppliers, Manufacturers

1. Management and tracking of supplies and track (Warehouse management, Order Management, Delivery Management and Asset Tracking, Supplier Management)

2. Mobile-enabled inventory management (RFIDs, GPS, etc), e.g. smartphones with barcode recognition apps to track status of inventory

3. Real-time tracking and updating of activities using dashboards and analytics

4. Remote monitoring and control of plant equipment and operations

5. Peer to peer real-time payments

6. References and calculators (lab/clinical/medical references and calculators)

7. Mobile data to be integrated with backend systems e.g. ERP systems and all

Corporates/ Business

executives and decision makers

1. Enterprise BI—analytics, visualization, dashboards and reports on web and mobile devices for effective executive decision support

2. Workplace productivity enhancement

4. Enhancement of the brand image on the social network

5. Collaboration across different teams/segments, sharing latest

6. Stakeholder connectivity improvement

Regulatory Agencies

1. Timely and accurate dissemination of regulatory information to patients/HCPs/other stakeholders e.g. info on safety/side effects, drug shortages, counterfeits, etc.

2. Real-time dissemination of advisory information to a large set of consumers real-time e.g. disease outbreak and mitigation information, travel advisory, etc


Patients





















group etc.)






Support Staff























Regulatory Agencies
































Database design (to be done preferably with standard pages)

QC of database before moving the same into production (with standard check-list as applicable)

Creation of dashboards depicting gaps

Figure 4: Data Capture and Mitigation of procedural gaps for database design

Data Capture: Mitigation of Gaps



CRO 2 CRO 3 CRO 1

Company 20 Company 19 Company 18 Company 14 Company 15 Company 16 Company 17 Company 13 Company 12 Company 11 Company 10

Company 9 Company 8 Company 7 Company 6 Company 5 Company 4 Company 3 Company 2 Company 1

0.1 0.1 0.2

0.6 1.0 1.1 1.2 1.2 1.2 1.2

1.4 1.5

2.4 3.8

4.6 6.4

6.6 6.8

7.4 8.4

9.4 13.0

17.4

Percentage distribution of apps across leading Life Sciences companies

Company 17

Company 10

Company 6

Company 4

Company 8

Company 5

Company 3

Company 7

Company 2

Company 1

Company 9

Revenues

Apps/Billion

Research based on the study of approximately 1100 published apps of leading pharma companies across multiple mobile platforms

*Revenue and Apps/billion data has been brought to a common scale0 10 20 30 40 50 60 70

Note – Check References Section 5 on Page 17 for short description of the companies

App distribution across therapeutic areasWe have observed that oncology and chronic diseases (CVS, metabolic/lifestyle disorders and allergy + infectious diseases, etc) are the top focus areas when it comes to investment in mobile apps by the pharma companies. This can be primarily attributed to the fact that these conditions have a global incidence and are usually long term with multiple contributing etiological factors and assessments to be conducted at fairly regular intervals. Hence, effective patient self-management (ensuring adherence to the treatment regime, self-monitoring aids to track progress, regular sync up with providers, etc) is of utmost importance.

App distribution across various categories It has been observed that other than medical knowledge-related apps, apps for patient awareness, participation and self-management of disease are highest in number, reflecting a trend towards patient-centricity and empowerment. Drug and treatment adherence and disease tracking apps are being used for increasing patient compliance, potentially aimed at increasing sales and outcomes.



Rare/Genetic Diseases

Vaccines

Clinical Trial

Tobacco/Smoking Cessation related

Autoimmune/Autoinflammatory/Idiopathic

Nephrology

Women's Health

Orthopedics & Rheumatology

Dermatology

Respiratory

Pediatrics

Reproductive Medicine

Healthy Living/Fitness

Crop Science

Ophthalmology

Neuroscience/Neurological

Animal Health

Allergy + Infectious diseases

Metabolic/Lifestyle Disorders

CVS

Oncology

0.9

1.0

1.4

1.4

1.5

1.7

1.7

1.8

1.9

2.2

2.2

2.4

2.4

2.8

3.4

4.3

4.5

6.3

6.8

7.6

10.0

Percentage distribution of mobile apps across therapeutic areas


ERP/CRM

Business/Financials

Animal Health

Healthy Living/Fitness

SafesForce enablement

Disease Outbreak Info/Disease Surveillance

Workplace productivity

Clinical Trials /Workflow

Gaming Apps

Meetings/Events/Scientific-Medical Conference/Crowdsourcing platforms

Product info/Tutorials/Catalogues/Sales Tool

Medical calculator/Risk Estimators

Adherence/Tracker/Reminder/Alerts/Guides

Medical Knowledge and Collaboration (Drug references, clinical

Patient Awareness/Disease Management/Patient Engagement

0.2

0.4

0.5

0.7

0.7

1.0

1.8

1.9

4.4

7.7

9.3

12.1

12.4

18.6

22.2

Percentage distribution of mobile apps across categories


App distribution across user groupsA dynamically evolving clinical, regulatory and business landscape is compelling the life sciences industry to embrace mobile to internally streamline processes, accelerate time-to-market and externally reach out to a broader and comprehensive customer base. In the following table, we look at how mobile apps are critical to each of the key user groups in the Pharmaceutical Ecosystem.




Patients





















group etc.)






Support Staff























Regulatory Agencies






Patients





















group etc.)






Support Staff























Regulatory Agencies




Patients





















group etc.)






Support Staff























Regulatory Agencies



It has been observed that the top two focus user groups for mobile apps are the healthcare professionals (HCPs), including caregivers, trial support staff, sales representations, and the patients/subjects themselves. These two focus groups are the largest consumers of the products and services of the pharma companies and hence it is understandable that most of the apps are directed toward improving the engagement with them.

39

35

23

2

Percentage distribution of mobile apps across user groups

Healthcare Professionals/Caregivers, Trial support staff, Sales Representatives

Patients/Subjects

All User Groups

Employees




Key Actions Impact How HCL can help

Create apps with more integrated functionalities with increased attention to data security and privacy

Collaborate with other stakeholders in the digital

partner and cloud innovation.

Enable innovation and new business models by exposing services to entrepreneurial developers. Improve consumer experience and loyalty.

apps as innovation engines.

pharma organizations on mobility

which can help reduce cycle time while increasing customer experience.

Enable simultaneous multi country rollout

By releasing apps globally

company can increase the user base. It is also critical to note that at times speed-to-market can be a critical

higher adoption.

apps are launched regionally and

partners, design and creation agencies, translation services, resulting in inconsistency in

languages, ensuring that an app is released globally.

mobile application development

reusable components rather

development across organization.

Increase user retention by developing relationships beyond the app

retention including increased app usage.

Enable customer

media.

implementing strategies to use social media to promote mobile apps and build the brand.

to make apps more addictive

apps do not get ignored, abandoned or deleted, as

people to keep coming back.

Create an enriching and consistent user experience leading to brand loyalty

Considering that many

to support consumers who would be using their

great user experience with relevant content can improve stickiness.

real-time, omnichannel experience

brand value and loyalty thereby increasing adoption.

content with standards and guidelines – leading to consistent brand representation

including interactive data visualization, personalization

customer segments.

metrics around app popularity/usage/ potential value delivered to understand

engagement

Sentiment analysis, most importantly a continuous

metrics, can help in taking corrective actions to increase

real-time analytics and decision support.

Adapt to the

mobile landscape

Ensure that the apps are universally compatible and interoperable across all devices.

Enterprises need to be

changes across the various

will help in improving the therapeutic management.

market readiness with every new major technology releases.

and its micro vertical domain

mobile technologies.

381

186

133

63 30

9 6 0

50

100

150

200

250

300

350

400

450 Apps Distribution by Geo

47%

23%

16%

8%

4% 1% 1%

0%

5%

10%

15%

20%

25%

30%

35%

40%

45%

50% Percentage Distribution of Apps by Geo


)#6&

#2&

*778

&)#

6&#2

&*7

78&

9:;&

Global EU NA APAC SA/LATAM ME Africa

Global EU NA APAC SA/LATAM ME Africa

Factors Influencing the Adoption of Mobile AppsWhile pharma companies have been fairly consistent in releasing mobile apps, they have not enjoyed the kind of success with the usage of their apps as much as they would have desired. A research by research2guidance, “Pharma App Market Benchmarking 2014”, has shown that the leading Pharma companies have been able to generate 6.6 million downloads since 2008 and have less than 1 million active users. This kind of active user base is disappointing if we consider that quite a few of the mobile apps are launched to support blockbuster drugs which have millions of users globally.

There can be many reasons for low adoption. Some of them are listed below:

Apps are launched for specific countries and not globally alwaysIt has been observed that in quite a few cases, pharma companies do not launch their apps globally; rather they launch it in a handful of countries such as US, UK, Japan, Germany, and Netherlands, and only in some cases, in developing countries. As shown in the following diagram, more than 50% of the apps are not launched globally, and are concentrated around a few countries.



New Zealand

Zimbabwe

South Africa

Mexico

India

Austria

Turkey

Belgium

South Korea

Spain

Canada

China, Japan, Hongkong

Switzerland

Australia

Brazil

Netherlands

France

Italy

UK

Germany

US

0.3

0.3

0.8

0.9

1.1

1.4

1.4

1.6

1.6

2.5

2.8

2.8

2.8

4.4

5.0

5.2

5.4

5.5

7.7

9.6

36.6


Percentage distribution of mobile apps across countries

This limits the target user base for the apps. Considering the fact that many of the developing countries now have a high smartphone penetration and increased mobile connectivity, global launch of apps by pharma companies instead of in a few local markets could help increase the user base of the mobile apps and the number of active users.

Focus of mobile apps is specific to therapeutic areas or in some cases even blockbuster drugsIt has been observed that quite a few of the mobile apps of pharma companies are focused only on the therapeutic areas that are top priorities for them. Also, within the specific therapeutic areas, sometimes the focus is around developing apps for specific drugs that are getting rolled into the market. Hence, the target user bases for these kinds of apps are always lower in comparison to generic mHealth apps. Embedding additional functionalities around general health tracking features and related information content in the drug specific apps when launching them can greatly improve the situation.




Patients





















group etc.)






Support Staff























Regulatory Agencies



Untested efficacy of the apps may compromise safetyThe efficacy of the apps can be a cause for concern at times. Considering that wrong information or wrong results can also lead to fatal consequences, the accuracy of the functions has to be 100%. Examples: A top pharma’s (headquartered in Belgium) PASI Calculator did not cite the source used to perform calculations, another top pharma company’s Rheumatology Calculator App had to be recalled due to a bug in the app which was giving wrong results. This puts the focus on testing and certifications. Some app certification programs are already emerging—like the National Health Service online Health Apps Library in the UK and FDA-approved apps in the US. Customers would be more comfortable to use the mobile apps if certification programs are made mandatory and universal.

Concerns around data security and privacyThe pharma and healthcare sector deals with sensitive, personal and identity data of customers and hence data security and privacy is of paramount importance. According to the European Commission, most pharma and mHealth apps collect large quantities of information (e.g. data stored by the user on the device and data from different sensors, including location). This is at times processed in third-world countries outside the European Economic Area, which may not have the same security standards in place. In order to increase adoption of the apps, pharma companies need to create confidence among the users that their privacy and confidentiality would be protected.

Limited adoption of mobility best practicesPharma companies need to focus on perfecting the art of app creation, publishing and increasing adoption in a way that it optimizes the resources of the IT team through reusability and easy maintainability. It also contributes to a uniform brand image.

Example: One area of improvement can be the app publishing entities. As per the research2guidance report, one of the large global pharma companies use up to 17 different app publishing entities. This limits reusability of knowledge, technology components and standard functionalities.



Description Pseudonyms

A large Swiss multinational pharmaceutical company Company 1

A New Jersey based global pharmaceutical company, with operations in more than 140 countries and dealing medicines, vaccines, biologic therapies, and animal health products

Company 2

A large German multinational chemical and pharmaceutical company Company 3

A US multinational pharma, devices, diagnostics, biologics, consumer health company, headquartered in New Jersey Company 4

A Swiss multinational pharmaceutical, diagnostics and biotech company with a focus on Diabetes management Company 5

A US multinational pharmaceutical corporation Company 6

A British-Swedish multinational pharmaceutical and biologics company Company 7

A French multinational pharmaceutical company Company 8

A global pharma, animal health, bio-therapeutics company headquartered at Germany Company 9

A British multinational pharmaceutical company with a focus on Pharma, Vaccines and Consumer Health Company 10

A US multinational biotech company Company 11

A global pharma company headquartered in Israel Company 12

A top 20 Japanese pharma company Company 13

A research-based pharmaceuticals company post spinoff, headquartered in US Company 14

A Japanese pharma company Company 15

An American pharma company headquartered in New York Company 16

A New Jersey based global pharmaceuticals company with operations in more than 125 countries and the pioneers of world's 1st antibiotic production

Company 17

An American biotechnology company Company 18

A Danish multinational pharmaceutical company Company 19

A Japanese pharmaceutical with a focus on Neuro and Onco products Company 20

One of the largest CROs headquartered in New Jersey CRO 1

A China-based R&D CRO servicing Pharma, Biotech, Med Devices Companies CRO 3

World's largest bio-pharma CRO headquartered in US CRO 2


Patients





















group etc.)






Support Staff























Regulatory Agencies



Where HCL Can Help














higher adoption.









Enable customer

media.













customer segments.


engagement




Adapt to the

mobile landscape





















higher adoption.









Enable customer

media.













customer segments.


engagement




Adapt to the

mobile landscape










Reference1. The Royal Colleague of Physicians (RCP): Be Clear About Clinical Best

Practice for Medical Apps, May 2014. https://www.integratedchange.net/be-clear-about-clinical-best-practice-for-medical-apps (Accessed on 03-08-2015).

2. How is mobility driving business for pharmaceutical companies?, PwC, Nov 2012, 1 - 4. E-Book.

3. Mobihealthnews: Pew: 19 percent of smartphone users have health apps, November 2012, http://mobihealthnews.com/18965/pew-19-percent-of-smartphone-users-have-health-apps/ (Accessed on 02-08-2015).

4. JMIR Mhealth Uhealth: mHealth 2.0: Experiences, Possibilities, and Perspectives, May 2014, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114478/(Accessed on 15-08-2015)

5. FierceMobile Healthcare: Report: Diabetes mobile app usage falling short, January 2014, http://www.fiercemobilehealthcare.com/story/report-diabetes-mobile-app-usage-falling-short/2014-01-26 (Accessed on 26-07-2015)

6. Techila Solutions: Mobile app playing an important role in HealthCare industry, http://www.techilasolutions.com/mobile-app-playing-an-important-role-in-healthcare-industry/ (Accessed on 10-08-2015)

7. Booz & Company Inc.: M-Health Physician use of mobile technology, http://www.strategy-business.com/The_Advent_of_Digital_Health/ (Accessed on 12-08-2015)

8. TaylorWessing: Mobile medical apps in Europe, http://www.taylorwessing.com/synapse/ti_mobile_med_apps.html, (Accessed on 12-08-2015)

9. HIMSS: Privacy and Security Concerns: Highlights, http://www.himss.org/ResourceLibrary/GenResourceDetail.aspx?ItemNumber=30406, (Accessed on 13-08-2015)

10. research2guidance: Why Pharma companies have no substantial impact on the mHealth app economy, October 2014, http://research2guidance.com/why-pharma-companies-have-no-substantial-impact-on-the-mhealth-app-economy/ (Accessed on 13-08-2015)

11. in-Pharma Technologist.com: MHRA and Novartis lead consortium to develop adverse drug reaction app by Dan Stanton, September 2014, http://www.in-pharmatechnologist.com/Regulatory-Safety/MHRA-and-Novartis-lead-consortium-to-develop-adverse-drug-reaction-app,

(Accessed on 15-08-2015)12. Examination of clinical trial costs and barriers for drug development,

Eastern Group Research, Inc., July 25 2014, Pg. xiii. E-Book.13. Kony: Industry Solutions Life Sciences,

http://www.kony.com/solutions/industry-solutions-life-sciences, (Accessed on 13-08-2015)

14. Pew Research Center: Health Fact Sheet, http://www.pewinternet.org/fact-sheets/health-fact-sheet/, (Accessed on 14-08-2015)

15. Green Paper on mobile Health, European Commission, April 2014, 7 - 8. E-Book.

16. Healthcare Mobile Applications, http://www.pocket.md/healthcare-mobile-applications.html

17. Research Details:

Study of 1089 published apps across multiple mobile platforms for 23 leading pharma companies conducted in May 2015Company descriptions

Reference1. The Royal Colleague of Physicians (RCP): Be Clear About Clinical Best

Practice for Medical Apps, May 2014. https://www.integratedchange.net/be-clear-about-clinical-best-practice-for-medical-apps (Accessed on 03-08-2015).

2. How is mobility driving business for pharmaceutical companies?, PwC, Nov 2012, 1 - 4. E-Book.

3. Mobihealthnews: Pew: 19 percent of smartphone users have health apps, November 2012, http://mobihealthnews.com/18965/pew-19-percent-of-smartphone-users-have-health-apps/ (Accessed on 02-08-2015).

4. JMIR Mhealth Uhealth: mHealth 2.0: Experiences, Possibilities, and Perspectives, May 2014, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114478/(Accessed on 15-08-2015)

5. FierceMobile Healthcare: Report: Diabetes mobile app usage falling short, January 2014, http://www.fiercemobilehealthcare.com/story/report-diabetes-mobile-app-usage-falling-short/2014-01-26 (Accessed on 26-07-2015)

6. Techila Solutions: Mobile app playing an important role in HealthCare industry, http://www.techilasolutions.com/mobile-app-playing-an-important-role-in-healthcare-industry/ (Accessed on 10-08-2015)

7. Booz & Company Inc.: M-Health Physician use of mobile technology, http://www.strategy-business.com/The_Advent_of_Digital_Health/ (Accessed on 12-08-2015)

8. TaylorWessing: Mobile medical apps in Europe, http://www.taylorwessing.com/synapse/ti_mobile_med_apps.html, (Accessed on 12-08-2015)

9. HIMSS: Privacy and Security Concerns: Highlights, http://www.himss.org/ResourceLibrary/GenResourceDetail.aspx?ItemNumber=30406, (Accessed on 13-08-2015)

10. research2guidance: Why Pharma companies have no substantial impact on the mHealth app economy, October 2014, http://research2guidance.com/why-pharma-companies-have-no-substantial-impact-on-the-mhealth-app-economy/ (Accessed on 13-08-2015)

11. in-Pharma Technologist.com: MHRA and Novartis lead consortium to develop adverse drug reaction app by Dan Stanton, September 2014, http://www.in-pharmatechnologist.com/Regulatory-Safety/MHRA-and-Novartis-lead-consortium-to-develop-adverse-drug-reaction-app,



(Accessed on 15-08-2015)12. Examination of clinical trial costs and barriers for drug development,

Eastern Group Research, Inc., July 25 2014, Pg. xiii. E-Book.13. Kony: Industry Solutions Life Sciences,

http://www.kony.com/solutions/industry-solutions-life-sciences, (Accessed on 13-08-2015)

14. Pew Research Center: Health Fact Sheet, http://www.pewinternet.org/fact-sheets/health-fact-sheet/, (Accessed on 14-08-2015)

15. Green Paper on mobile Health, European Commission, April 2014, 7 - 8. E-Book.

16. Healthcare Mobile Applications, http://www.pocket.md/healthcare-mobile-applications.html

17. Research Details:

Study of 1089 published apps across multiple mobile platforms for 23 leading pharma companies conducted in May 2015Company descriptions




Company 2
















Company 17







AcknowledgementsThe development of this paper has benefited from the input and support provided by the following contributors:• Karthik Ponnusamy – Business Solutions Group, Life Sciences, HCL

Technologies Limited• Sri Krishna Nandanamudi – Business Solutions Group, Life Sciences,

HCL Technologies Limited• Vijai Krishna Podicheti – Business Solutions Group, Life Sciences, HCL

Technologies Limited






Company 2
















Company 17







CRO = Contract Research Organization


Aditi ChakrabortyAditi has close to 7 years of experience in the IT industry with a specific focus on the Pharma and Life Sciences vertical. She has worked in the areas of data model mapping, pharma data standards like SEND and SDTM, drug safety and efficacy, collaboration and search platforms and managing implementation of new study categories such as Medical countermeasures (animal model studies).

Prior to HCL, Aditi worked at PointCross Inc. where she was a business analyst cum Pre-Sales subject matter expert. She was involved in Pre-Sales and Solution Consulting and was also involved in high level product design & workflow inputs for the software development team.

At HCL, Aditi is a part of the Life Sciences Business Solutions Group. She is responsible for bid management and analysing and identifying white spaces for building business propositions in the Pharma and Life Sciences space.Aditi is an M.V.Sc graduate in Pharmacology and Toxicology with a Post Graduate diploma in Bioinformatics.













higher adoption.









Enable customer

media.













customer segments.


engagement




Adapt to the

mobile landscape









Please feel free to write to us at [email protected]

HCL Life Sciences & HealthcareHCL is a leading provider of Life Sciences and Healthcare Business and Technology services. We are the chosen service provider for enabling new growth drivers for our clients, providing them with industry leading best practices, taking care of their compliance needs and ensuring goldstandard process cycle times. Our clientele includes seven of the top ten global pharmaceutical companies, seven of the top ten medical devices companies, six of the top ten health plans, three of the top five CRO’s and two of the top three data providers. Equipped with certified technologyexperts and domain specialists, HCL offers services in critical areas of the life sciences and healthcare eco system such as drug discovery, clinical development, drug safety, regulatory compliance, manufacturing and plant automation, commercial, Healthcare analytics, Population Health Management [PHM], mHealth, member experience management [MEM], fraud, waste and abuse management [FWA].

Let’s connect:


ABOUT HCLAbout HCL TechnologiesHCL Technologies is a leading global IT services company working with clients in the areas that impact and redefine the core of their businesses. Since its emergence on the global landscape, and after its IPO in 1999, HCL has focused on ‘transformational outsourcing’, underlined by innovation and value creation, offering an integrated portfolio of services including software-led IT solutions, remote infrastructure management, engineering and R&D services and business services. HCL leverages its extensive global offshore infrastructure and network of offices in 31 countries to provide holistic, multi-service delivery in key industry verticals including Financial Services, Manufacturing, Consumer Services, Public Services and Healthcare & Life sciences. HCL takes pride in its philosophy of ‘Employees First, Customers Second’ which empowers its 106,107 transformers to create real value for customers. HCL Technologies, along with its subsidiaries, had consolidated revenues of US$ 6 billion, for the Financial Year ended as on 30th June 2015 (on LTM basis).For more information, please visit www.hcltech.com

About HCL EnterpriseHCL is a $6.9 billion leading global technology and IT enterprise comprising two companies listed in India – HCL Technologies and HCL Infosystems. Founded in 1976, HCL is one of India’s original IT garage start-ups. A pioneer of modern computing, HCL is a global transformational enterprise today. Its range of offerings includes product engineering, custom & package applications, BPO, IT infrastructure services, IT hardware, systems integration, and distribution of information and communications technology (ICT) products across a wide range of focused industry verticals. The HCL team consists of over 110,000 professionals of diverse nationalities, who operate from 31 countries including over 505 points of presence in India. HCL has partnerships with several leading global 1000 firms, including leading IT and technology firms.For more information, please visit www.hcl.com

Hello there! I am an Ideapreneur. I believe that sustainable business outcomes are driven by relationships nurtured through values like trust, transparency and flexibility. I respect the contract, but believe in going beyond through collaboration, applied innovation and new generation partnership models that put your interest above everything else. Right now 110,000 Ideapreneurs are in a Relationship Beyond the Contract™ with 500 customers in 31 countries. How can I help you?


Date post:	14-Jun-2020
Category:	Documents
Upload:	others
View:	1 times
Download:	0 times

The Mobile App Ecosystem in Pharma - HCL Technologies€¦ · and how HCL can provide solutions to...

Documents